一个基于三甲基锁定聚碳酸的新型氧化敏感药物输送系统
Dongdong Wang1, Mu Li1, Hanning Zhang1
1State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Biomedical Materials and Engineering Research Center of Hubei Province, Wuhan University of Technology, Wuhan 430070, China.
Biomacromolecules
|August 16, 2023
概括
新型聚合物纳米载体对瘤微环境做出反应,用于向癌症治疗. 这些基于MTC的细胞在NQO1酶存在时特别释放药物,提高了治疗的精度.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 响应刺激的聚合物纳米载体在癌症治疗中提供可控的药物释放.
- NAD(P) H:氨酸氧降解酶1 (NQO1) 在瘤中被上调,可以激活前体药物.
- 向NQO1提供了酶介导药物递送的策略.
研究的目的:
- 合成一种新型的氧化还原敏感单体 (MTC) 用于对刺激有反应的聚合物纳米载体.
- 开发基于MTC的两类块共聚合物,并将其自组装成微粒.
- 评估这些纳米细胞在NQO1介导的瘤微环境中的药物传递潜力.
主要方法:
- 一种新型氧化还原敏感碳酸单体 (MTC) 的合成.
- 通过环开放聚合制备两类块共聚合物.
- 聚乙烯甘醇-b-PMTC自组装成用于 doxorubicin (DOX) 封装的小粒.
- 在体外评估对氧化还原反应药物释放,生物相容性和血液相容性.
- 评估NQO1酶介导的药物释放和细胞毒性.
主要成果:
- 成功合成了MTC单体和制备的聚乙烯糖醇-b-PMTC块共聚合物.
- 聚合物微粒有效地封装了多克索鲁比辛 (DOX),并表现出氧化还原反应药物释放.
- 试验室研究证实了纳米细胞的优良生物相容性和血液相容性.
- 在NQO1受阻细胞中,药物释放显著减少,表明酶特异性释放.
- 在存在NQO1酶抑制剂时,细胞毒性降低,表明药物向输送.
结论:
- 基于MTC的聚碳酸菌体显示出高效的药物封装和刺激响应释放.
- 这些纳米细胞显示出在NQO1-过度表达的瘤中具有向药物递送的潜力.
- 这个平台为癌症治疗中的智能纳米载体提供了一个有希望的方法.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.


